Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia

被引:41
|
作者
Koziel, H
Kim, S
Reardon, C
Li, XH
Garland, R
Pinkston, P
Kornfeld, H
机构
[1] Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Boston Med Ctr, Div Pulm & Crit Care, Boston, MA USA
关键词
D O I
10.1164/ajrccm.160.6.9902099
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV-1 RNA levels in other compartments, such as the lungs, is not well characterized. The purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RNA in cell-free bronchoalveolar lavage fluid (BALF) with that in serum. Specimens were examined from 77 HIV-seropositive adults (CD4(+) cell counts: 0 to 700 cells/mm(3); 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic individuals who were compared with 34 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1), Aspergillus sp. (n = 1), or pulmonary Kaposi's sarcoma (n = 1). For serum HIV-1 RNA, the proportion of subjects with detectable levels and the mean values were similar for asymptomatic individuals and persons with active lung disease (85% versus 86%, respectively) (6.64 x 10(4) versus 1.81 x 10(5) HIV-1 RNA copies/ml; p = 0.13). In contrast, HIV-1 RNA in BALF was more often detected (16% versus 62%; p = 0.001), and mean values were higher(1.04 x 10(5) versus 3.31 x 10(6) HIV-1 RNA copies/ml; p = 0.032), in subjects with active lung disease than in asymptomatic subjects, independent of early or advanced clinical stages of HIV-related disease. For both study groups, HIV-l RNA levels in BALF exceeded those in serum in 56% of cases by up to 66-fold, and did not correlate with local levels of tumor necrosis factor-alpha granulocyte-macrophage colony-stimulating factor, or interleukin-16. HIV-1 proviral DNA in cells from BALF was detected in up to 86% of subjects, more frequently in persons with advanced HIV disease (p = 0.0496), and often involved > 10% of BALF cells, but did not correlate with HIV-1 RNA detected in BALF. These data provide evidence for active HIV-1 replication in the lungs. HIV-1 replication is compartmentalized relative to serum, may be restricted, is independent of HIV-1 proviral DNA and clinical stage of HIV, and may be influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific factors. The lungs represent a large reservoir for HIV-1, and may present a source of persistent HIV-1 replication even during periods of apparent clinical latency of HIV-1 infection.
引用
收藏
页码:2048 / 2055
页数:8
相关论文
共 50 条
  • [31] BACTERIAL PNEUMONIA IN PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    HIRSCHTICK, RE
    GLASSROTH, J
    JORDAN, MC
    WILCOSKY, TC
    WALLACE, JM
    KVALE, PA
    MARKOWITZ, N
    ROSEN, MJ
    MANGURA, BT
    HOPEWELL, PC
    STANSELL, J
    TURNER, J
    OSMOND, D
    MERRIFIELD, C
    MOSSAR, M
    HIRSCHTICK, R
    MEISELMAN, L
    MANGHISI, KJ
    SCHNEIDER, RF
    REICHMAN, LB
    MANGURA, B
    BARNES, S
    RICHER, B
    AU, J
    COULSON, A
    CLEMENTE, V
    SARAVOLATZ, LD
    JOHNSON, C
    HUITSING, J
    KRYSTOFORSKI, A
    POOLE, WK
    RAO, AV
    CLAYTON, K
    HANSON, N
    JORDAN, M
    THOMPSON, J
    MYERS, D
    LAVANGE, L
    KATZIN, J
    FULKERSON, W
    WILCOSKY, T
    LOU, Y
    KALICA, AR
    WITTES, J
    FOLLMANN, D
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13): : 845 - 851
  • [32] Diagnosis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients with polymerase chain reaction:: A blinded comparison to standard methods
    Torres, J
    Goldman, M
    Wheat, LJ
    Tang, X
    Bartlett, MS
    Smith, JW
    Allen, SD
    Lee, CH
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) : 141 - 145
  • [33] PRIMARY DAPSONE CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN IMMUNOCOMPROMISED PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
    LUCAS, CR
    SANDLAND, AM
    MIJCH, A
    SIMPSON, JM
    MEDICAL JOURNAL OF AUSTRALIA, 1989, 151 (01) : 30 - 33
  • [34] PYRIMETHAMINE/SULFADOXINE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    JURADO, R
    GARCIAHEROLA, A
    GARCIALAZARO, M
    KINDELAN, JM
    VILLANUEVA, JL
    TORRECISNEROS, J
    CLINICAL INFECTIOUS DISEASES, 1994, 19 (01) : 218 - 219
  • [35] Hydroxyurea to inhibit human immunodeficiency virus-1 replication
    Romanelli, F
    Pomeroy, C
    Smith, KM
    PHARMACOTHERAPY, 1999, 19 (02): : 196 - 204
  • [36] Pneumocystis Pneumonia Associated with Human Immunodeficiency Virus
    Miller, Robert F.
    Huang, Laurence
    Walzer, Peter D.
    CLINICS IN CHEST MEDICINE, 2013, 34 (02) : 229 - +
  • [37] Critical Crossroads in the Care of Human Immunodeficiency Virus-Infected Persons
    Crum-Cianflone, Nancy
    CRITICAL CARE MEDICINE, 2013, 41 (06) : 1579 - 1580
  • [38] INTRAMUSCULAR PENTAMIDINE FOR THE PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    CHEUNG, TW
    MATTA, R
    NEIBART, E
    HAMMER, G
    CHUSID, E
    SACKS, HS
    SZABO, S
    ROSE, D
    CLINICAL INFECTIOUS DISEASES, 1993, 16 (01) : 22 - 25
  • [39] Survival of human immunodeficiency virus-infected persons with pulmonary tuberculosis
    Wood, R
    Post, FA
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1997, 1 (01) : 87 - 87
  • [40] Cytomegalovirus cavitary pneumonia in a human immunodeficiency virus-infected patient
    Sunanaga, Yusuke
    Suetsugu, Takayuki
    Nagata, Yusuke
    Miyata, Marina
    Kondo, Kiyotaka
    Mitsuyama, Hideo
    Kubota, Shingo
    Mizuno, Keiko
    Tanaka, Kentaro
    Inoue, Hiromasa
    RESPIROLOGY CASE REPORTS, 2024, 12 (05):